Brian K. Meyer is a Principal Scientist in Bioprocess Research and Development, Merck Research Laboratories. He completed his Ph.D. at The Pennsylvania State University. He has held various positions at Merck, both in the research and manufacturing divisions.


Here we report the results of intradermal vaccination studies that were performed with an attenuated virus (varicella; ZOSTAVAX®). Intradermal vaccination using the MicronJet™ by Nanopass Technologies was compared to the current route of administration (subcutaneous). It was demonstrated with ZOSTAVAX® that doses of 1/3rd and 1/10th the full dose elicited both antibody and T-cell responses that were equivalent to a full dose delivered subcutaneously. A full dose of ZOSTAVAX® administered intradermally resulted in a higher overall antibody titer when compared to the subcutaneous route.

Speaker Presentations

Speaker PDFs

Speaker PPTs

Download PPT